New treatment approaches in metastatic renal cell carcinoma

Current Opinion in Urology

Volumn 16, Issue 5, 2006, Pages 337-341

  Mancuso, Andrea ^a   Sternberg, Cora N ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Antiangiogenic therapy; New regimens; Renal cancer; Targeted therapies

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ALPHA INTERFERON; AP 23573; AXITINIB; BEVACIZUMAB; CGP 69846A; ERLOTINIB; EVEROLIMUS; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAF PROTEIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS DISEASE; PRIORITY JOURNAL; RASH; REVIEW; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; IMIDAZOLES; INDAZOLES; INDOLES; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; PYRROLES; QUINAZOLINES; SIROLIMUS; SULFONAMIDES;

EID: 33747197773     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mou.0000240305.78205.77     Document Type: Review

References (28)

1. Mancuso A, Sternberg CN. New treatments for metastatic kidney cancer. Can J Urol 2005; 12:66-70.
2. Bukowski RM. Renal cell carcinoma: a new era? Clin Genitourin Cancer 2005; 4:155.
3. Cohen HT, McGovern FJ. Medical progress: renal-cell carcinoma. N Engl J Med 2005; 353:2477-2490.
4. Mancuso A, Sternberg CN. What's new in the treatment of metastatic kidney cancer? BJU Int 2005; 95:1171-1180.
5. Lindsey H. Bevacizumab and erlotinib show promise for kidney cancer. Lancet Oncol 2006; 7:15.
6. Stadler WM. Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 2005; 104:2323-2333.
7. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315:971-979.
8. Rini BI, Sosman JA, Motzer RJ. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int 2005; 96:286-290.
9. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24. This study provides the first evidence of significant activity and probably an impact on overall survival especially compared with prior results in cytokine failures.
10. Motzer RJ, Rini BI, Michaelson MD, et al. Sunitinib maleate (SU11248) shows antitumor activity in patients with metastatic renal cell carcinoma: updated results from phase II trials. Eur J Cancer 2005; 3:227 [abstract 797].
11. Rini BI. Sorafenib. Expert Opin Pharmacother 2006; 7:453-461.
12. Ratain MJ, Eisen T, Stadler WM, et al. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of Sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005; 23(Pt I, Suppl) [2005 ASCO Annual Meeting Proceedings, abstract 4544].
13. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor Sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. Eur J Cancer 2005; 3:226 [abstract 794].
14. Lamuraglia M, Lassau N, Chami L, et al. Doppler ultrasonography with perfusion software and contrast agent injection as a tool for early evaluation of metastatic renal cancers treated with the Raf kinase and VEGFR inhibitor: a prospective study. J Clin Oncol 2005; 23(Pt I, Suppl) [2005 ASCO Annual Meeting Proceedings, abstract 3069].
15. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23:5474-5483.
16. Rini B, Rixe O, Bukowski R, et al. AG-013736, a multitarget tyrosine kinase receptor inhibitor, demonstrates antitumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer. J Clin Oncol 2005; 23(Pt I, Suppl) [2005 ASCO Annual Meeting Proceedings, abstract 4509].
17. Rixe O, Meric J, Bloch J, et al. Surrogate markers of activity of AG-013736, a multitarget tyrosine kinase receptor inhibitor, in metastatic renal cell cancer. J Clin Oncol 2005; 23(Pt I, Suppl) [2005 ASCO Annual Meeting Proceedings, abstract 3003].
18. Sternberg CN. Pazopanib (GW 780604): phase 1 and clinical development. First European International Kidney Cancer Symposium; April 2006; Madrid.
19. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434.
20. Hainsworth JD, Sosman JA, Spigel DR, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23:7889-7896. This study confirms evidence of 'cross talk' between EGFR and VEGF pathways.
21. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2001; 20:289-296.
22. Vogelzang NJ. Treatment options in metastatic renal carcinoma: an embarrassment of riches. J Clin Oncol 2006; 24:1-3.
23. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2006; 28:31-63.
24. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22:909-918.
25. Smith JW, Yo K-J, Dutcher J, et al. Update of a phase I study of intravenous CCI-779 given in combination with interferon-a to patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22(Suppl) [2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), abstract 4513].
26. Tabernero J, Rojo F, Burris H, et al. Phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors. J Clin Oncol 2005; 23(Pt I, Suppl) [2005 ASCO Annual Meeting Proceedings, abstract 3007].
27. Rivera VM, Kreisberg JI, Mita MM, et al. Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor. J Clin Oncol 2005; 23(Pt I, Suppl) [2005 ASCO Annual Meeting Proceedings, abstract 3033].
28. Bukowski RM, Negrier S, Elson P. Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res 2004; 10 (18 Pt 2):6310S-6314S.